{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:14:33Z","timestamp":1792588473277,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-023-01008-1","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T11:03:09Z","timestamp":1675508589000},"page":"2799-2804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study"],"prefix":"10.1007","volume":"23","author":[{"given":"Kenta","family":"Yagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Maruo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuka","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Ushio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kajizono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Niimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Izawa-Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,4]]},"reference":[{"key":"1008_CR1","doi-asserted-by":"publisher","first-page":"e0136324","DOI":"10.1371\/journal.pone.0136324","volume":"10","author":"F Ahmadizar","year":"2015","unstructured":"Ahmadizar F, Onland-Moret NC, De Boer A, Liu G, Maitland-van der Zee AH. Efficacy and safety assessment of the addition of bevacizumab to adjuvant therapy agents in cancer patients: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2015;10:e0136324. https:\/\/doi.org\/10.1371\/journal.pone.0136324.","journal-title":"PLoS ONE"},{"key":"1008_CR2","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","volume":"26","author":"HS Hochster","year":"2008","unstructured":"Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008;26:3523\u20139. https:\/\/doi.org\/10.1200\/JCO.2007.15.4138.","journal-title":"J Clin Oncol"},{"key":"1008_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.gore.2016.06.002","volume":"17","author":"BR Corr","year":"2016","unstructured":"Corr BR, Breed C, Sheeder J, Weisdack S, Behbakht K. Bevacizumab induced hypertension in gynecologic cancer: does it resolve after completion of therapy? Gynecol Oncol Rep. 2016;17:65\u20138. https:\/\/doi.org\/10.1016\/j.gore.2016.06.002.","journal-title":"Gynecol Oncol Rep"},{"key":"1008_CR4","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542\u201350. https:\/\/doi.org\/10.1056\/NEJMoa061884.","journal-title":"N Engl J Med"},{"key":"1008_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2016.09.024","volume":"70","author":"D Miles","year":"2017","unstructured":"Miles D, Cameron D, Bondarenko I, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer. 2017;70:146\u201355. https:\/\/doi.org\/10.1016\/j.ejca.2016.09.024.","journal-title":"Eur J Cancer"},{"key":"1008_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(12)70477-1.","journal-title":"Lancet Oncol"},{"key":"1008_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211036544","author":"SP Hack","year":"2021","unstructured":"Hack SP, Verret W, Mulla S, et al. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol. 2021. https:\/\/doi.org\/10.1177\/17588359211036544.","journal-title":"Ther Adv Med Oncol"},{"key":"1008_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","volume":"32","author":"S Sugawara","year":"2021","unstructured":"Sugawara S, Lee JS, Kang JH, et al. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2021;32:1137\u201347. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.004.","journal-title":"Ann Oncol"},{"key":"1008_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.amjmed.2021.09.010","volume":"135","author":"K Clarke","year":"2022","unstructured":"Clarke K, Adler N, Agrawal D, et al. Indications for the use of proton pump inhibitors for stress ulcer prophylaxis and peptic ulcer bleeding in hospitalized patients. Am J Med. 2022;135:313\u20137. https:\/\/doi.org\/10.1016\/j.amjmed.2021.09.010.","journal-title":"Am J Med"},{"key":"1008_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342. https:\/\/doi.org\/10.1056\/NEJMoa032691.","journal-title":"N Engl J Med"},{"key":"1008_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/cam4.3587","volume":"10","author":"K Yagi","year":"2021","unstructured":"Yagi K, Mitstui M, Zamami Y, et al. Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect. Cancer Med. 2021;10:164\u201372. https:\/\/doi.org\/10.1002\/cam4.3587.","journal-title":"Cancer Med"},{"key":"1008_CR12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/curroncol28010076","volume":"28","author":"AAT Uchiyama","year":"2021","unstructured":"Uchiyama AAT, Silva PAIA, Lopes MSM, et al. Proton pump inhibitors and oncologic treatment efficacy: a practical review of the literature for oncologists. Curr Oncol. 2021;28:783\u201399. https:\/\/doi.org\/10.3390\/curroncol28010076.","journal-title":"Curr Oncol"},{"key":"1008_CR13","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/apt.13588","volume":"43","author":"T Kagami","year":"2016","unstructured":"Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43:1048\u201359. https:\/\/doi.org\/10.1111\/apt.13588.","journal-title":"Aliment Pharmacol Ther"},{"key":"1008_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.22013","author":"R Ando-Matsuoka","year":"2022","unstructured":"Ando-Matsuoka R, Yagi K, Takaoka M, et al. Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells. Drug Dev Res. 2022. https:\/\/doi.org\/10.1002\/ddr.22013.","journal-title":"Drug Dev Res"},{"key":"1008_CR15","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ijc.21229","volume":"117","author":"Y Liu","year":"2005","unstructured":"Liu Y, Inoue M, Sobue T, Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer. 2005;117:662\u20136. https:\/\/doi.org\/10.1002\/ijc.21229.","journal-title":"Int J Cancer"},{"key":"1008_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1158\/1055-9965.EPI-10-1025","volume":"20","author":"T Shimazu","year":"2011","unstructured":"Shimazu T, Inoue M, Sasazuki S, et al. Plasma isoflavones and the risk of lung cancer in women: a nested case-control study in Japan. Cancer Epidemiol Biomark Prev. 2011;20:419\u201327. https:\/\/doi.org\/10.1158\/1055-9965.EPI-10-1025.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1008_CR17","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1158\/1078-0432.CCR-12-1257","volume":"18","author":"F Simpkins","year":"2012","unstructured":"Simpkins F, Hevia-Paez P, Sun J, et al. Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res. 2012;18:5911\u201323. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1257.","journal-title":"Clin Cancer Res"},{"key":"1008_CR18","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa032071","volume":"350","author":"RT Chlebowski","year":"2004","unstructured":"Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350:991\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa032071.","journal-title":"N Engl J Med"},{"key":"1008_CR19","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/ijc.32431","volume":"145","author":"N Mori","year":"2019","unstructured":"Mori N, Sawada N, Iwasaki M, et al. Circulating sex hormone levels and colorectal cancer risk in Japanese postmenopausal women: the JPHC nested case-control study. Int J Cancer. 2019;145:1238\u201344. https:\/\/doi.org\/10.1002\/ijc.32431.","journal-title":"Int J Cancer"},{"key":"1008_CR20","doi-asserted-by":"publisher","first-page":"e954","DOI":"10.1002\/onco.13735","volume":"26","author":"SY Kim","year":"2021","unstructured":"Kim SY, Lee JS, Kang J, et al. Proton pump inhibitor use and the efficacy of chemotherapy in metastatic colorectal cancer: a post hoc analysis of a randomized phase III trial (AXEPT). Oncologist. 2021;26:e954-62. https:\/\/doi.org\/10.1002\/onco.13735.","journal-title":"Oncologist"},{"key":"1008_CR21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/cancers12030640","volume":"12","author":"M Tozzi","year":"2020","unstructured":"Tozzi M, S\u00f8rensen CE, Magni L, et al. Proton pump inhibitors reduce pancreatic adenocarcinoma progression by selectively targeting H+, K+-ATPases in pancreatic cancer and stellate cells. Cancers. 2020;12:640. https:\/\/doi.org\/10.3390\/cancers12030640.","journal-title":"Cancers"},{"key":"1008_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/bjc.2011.201","volume":"105","author":"J Cassidy","year":"2011","unstructured":"Cassidy J, Clarke S, D\u00edaz-Rubio E, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer. 2011;105:58\u201364. https:\/\/doi.org\/10.1038\/bjc.2011.201.","journal-title":"Br J Cancer"},{"key":"1008_CR23","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666\u201376. https:\/\/doi.org\/10.1056\/NEJMoa072113.","journal-title":"N Engl J Med"},{"key":"1008_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.critrevonc.2019.09.003","volume":"143","author":"S Gori","year":"2019","unstructured":"Gori S, Inno A, Belluomini L, et al. Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. Crit Rev Oncol Hematol. 2019;143:139\u201347. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.09.003.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1008_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science. 2018;359:91\u20137. https:\/\/doi.org\/10.1126\/science.aan3706.","journal-title":"Science"},{"key":"1008_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","volume":"31","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and Poplar trials. Ann Oncol. 2020;31:525\u201331. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.006.","journal-title":"Ann Oncol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01008-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01008-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01008-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T17:14:01Z","timestamp":1696094041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01008-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,4]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["1008"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01008-1","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,4]]},"assertion":[{"value":"28 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All participants provided informed consent or gave them an opportunity to decline participation in the study by disclosure of information documents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was approved by the ethics committee of the University of Tokushima Hospital (approval number: 2962-3) and the protocol adhered to the tenets of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animals rights"}}]}}